ANN ARBOR, MI (July 26, 2004) – Velcura Therpeutics announced the development of a custom Affymetrix GeneChip array that aids the development of bone disease therapies by enabling researchers to follow global changes in gene expression during human bone formation.
Velcura worked with Affymetrix to design and produce the custom array. It is intended to help speed research to fight osteoporosis and other bone diseases.
DNA microarrays allow the human genome to be queried for changes in gene expression or variations in gene sequence. Approximately 1,500 genes were included on the chip. The array is only available for use within Velcura Therapeutics for its own studies or that of its partners.
Affymetrix is involved in DNA microarray technologies. Velcura Therapeutics, Inc. is involved in developing therapies for osteoporosis and other bone diseases.
